

In association with



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI



2nd School of **ACUTE LEUKEMIA**

JOIN US NOW!

Free Registration on
www.sohoitaly.it

28 - 29

Jun. 2022

Rome, Italy & Virtual

Hotel NH Collection
Roma Vittorio Veneto

Organizing secretariat



www.proeventi.it
info@proeventi.it

Follow Us!





Patronage



SIE
Società Italiana
di Ematologia



In Association with



Promoted by



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico


ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI





SUMMARY

With the Patronage	1
Summary	3
About SOHO Italy	4
Presidents	6
Scientific Board	7
Scientific Secretariat	8
Big Faculty	8
Young Faculty	9
Rationale	10
Key Information	12
General Information	13
Public Transport	14
Program Table	16
28 Jun	20
29 Jun	24





What is SOHO Italy?

The Italian Society of Hematologic Oncology is bringing together leading SOHO experts and top Italian researchers in acute leukemias, MPDs and MDSs, aims to consolidate the Italian Hematology-SOHO partnership.

Purpose

The aim of the association is the integration of the clinical-scientific activities of IRST Meldola and MD Anderson Cancer Center and the improvement of the clinical-therapeutic approach to patients with hematologic malignancies.

Represented by

The Society SOHO Italy is represented by G. Martinelli and C. Cerchione, IRST Meldola, and H. Kantarjian, E. Jabbour, M. Konopleva, N. Daver, MD Anderson Cancer Center.




President

Claudio Cerchione



Since 2018, he works in Hematology Unit of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS. He also has spent international research experiences in Friedrich-wilhelms universität, Bonn, Germany, in Universidade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he was nominated Ambassador of SOHO (Society of Hematologic Oncology). He is member of the editorial boards of many scientific journals, and member of several international societies, including the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH), European Hematology Association (EHA) and Italian Society of Hematology (SIE).

Hagop Kantarjian



Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003 - present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics.

Giovanni Martinelli



As of 1 January 2018, Professor Giovanni Martinelli is scientific director of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS, in Meldola (FC), Italy. Until December 2017, Professor Giovanni Martinelli was associate professor of Hematology at the Institute of Hematology "L. & A. Seragnoli", Azienda Ospedaliera S. Orsola - Malpighi at the University of Bologna, Italy. His main fields of research are AML, ALL and CML, including research on targeted therapies in major hematological syndromes: Acute Leukemias, CML (both Philadelphia-chromosome positive and non - positive), and hypereosinophilic syndrome.



Scientific Board



Cerchione Claudio



Locatelli Franco



Daver Naval G.



Martinelli Giovanni



De La Fuente Adolfo



Nitin Jain



Jabbour Elias



Saglio Giuseppe



Kantarjian Hagop



Konopleva Marina



Scientific Secretariat

C. Cerchione
N. Daver
B. Giannini
E. Jabbour
H. Kantarjian
M. Konopleva

F. Locatelli
G. Marconi
G. Martinelli
G. Musuraca
M. Norata
G. Saglio

Big Faculty

C. Cerchione
F. Ciceri
D. Cilloni
N. Daver
A. De La Fuente
S. Galimberti
C. Giallongo
M. Gottardi
I. Iacobucci
A. Isidori
E. Jabbour
H. Kantarjian
M. Konopleva
F. Lanza
F. Locatelli

G. Marconi
M.P. Martelli
G. Martinelli
J. Nitin
A. Olivieri
C. Papayannidis
C. Quintarelli
J. Ribera
G. Saglio



Young Faculty

TBD

Hematology Reports



ACUTE LEUKEMIA

Rationale

The last years have ushered in a new era in acute leukemia therapy, with the advent and approval of multiple targeted therapies. Additionally, an improved understanding of the immune system in patients with hematologic malignancies has resulted in major progress in the development of immune therapies for the treatment, including monoclonal antibodies with or without conjugated toxins (bacterial or chemical), bispecific T-cell engagers and DART antibodies, immune-checkpoint-based therapies, and CAR-T cell approaches.

At the same time, there is an increasing understanding of tumor biology, creating the rationale for new combinations of drugs and new therapy development.



The numerous ongoing trials evaluating these novel therapies, with well-designed correlative interrogations of the immune system in patients treated in such trials, will further enhance our understanding of immune therapies as single-agent and combination approaches for the treatment of acute leukemias.

In this scenario, our aim is to create a international team, integrating a big faculty composed by international experts, which will integrate with a group of young researchers with known experience in this disease ("SOHO Acute Leukemia cantera"), in order to share projects and preclinical and clinical new clinical trials, in different fields of these heterogeneous diseases.

The "cantera" (Under40) will be selected through projects' submission and CV evaluation, which will be performed by the big faculty, and will be able to be integrated in next editions.



Key Information

VENUE

NH Collection Roma Vittorio Veneto
Corso d'Italia, 1, 00198 Roma, Italy

MEETING


28 jun 2022
29 jun 2022

Ita	Tx
08.30 - 18.00	01.30 am - 11.00 pm
08.30 - 19.20	01.30 am - 12.20 pm

SOCIAL MEDIA

Soho Italy is active on various social media platform. Follow us on the networks below and get real-time updates:

 Facebook: Soho Italy

 Twitter: @sohoitaly

 Linkedin: Soho Italy

 Instagram: sohoitaly

#SOHOItaly2022

INTERNET

WiFi is available in all areas.





General Information

LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

CLIMATE

The average temperature is around 20 - 32 degrees.

BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

TAXI

The single number to call a taxi is 060609, for other utilities on the taxi service, see www.060608.it.





Public Transports

From Fiumicino Airport

Train: The hotel is located 30 km from the airport. You may take a train to Stazione Termini. From there, you can take the underground (Line A) and get off at either Barberini or Spagna.

Taxi: It's a 37 minutes trip and is around €65.

Aerobus shuttle: Departs every 30 - 45 minutes and costs 6€. Drop off at Stazione Termini and from there its the Bus line 910 toward Mancini for 4 stops.

From the train station

Closest metro station: Barberini

100min Ticket: 1.50€ 24h Ticket: 7.00€ 48h Ticket: 12.50€ 72h Ticket: 18.00€ 7-day Ticket: 24.00€

By car

The hotel's GPS Coordinates: 41.91018°N; 12.490303000000004°E

Parking: Offsite. €5/hour, €30-40 per day depending on the model of the car







Program Table

28 Jun

	Ita	Tx
08.00	08.30	01.30 am
09.00	Opening and introduction to the project	
	09.00	02.00 am
10.00	Biology and MRD Session	
11.00		
12.00		
	12.00	05.00 am
13.00	Acute Lymphoblastic Leukemia – What is changing?	
14.00		
15.00	15.00	08.00 am
16.00	Acute Lymphoblastic Leukemia - Toward a new world	
17.00		
18.00		
19.00		
20.00		
21.00		
16		



29 Jun

08.00

Ita

Tx

08.30

01.30 am

09.00

Opening of 2nd Day

09.00

02.30 am

10.00

Novel targets and target therapies in Acute Myeloid Leukemia

11.00

12.00

11.40

04.40 am

13.00

Particular settings in Acute Myeloid Leukemia

14.00

15.00

14.40

07.40 am

16.00

The revolution in Acute Myeloid Leukemia

17.00

18.00

17.20

10.20 am

19.00

Particular subsets of Acute Leukemia

20.00

21.00







28
06.22



08.30 Opening and introduction to the project
C. Cerchione, G. Martinelli

SESSION 1

BIOLOGY AND MRD SESSION

Chairs: S. Galimberti, C. Giallongo, I. Iacobucci

09.00 Impact of new opportunities in ALL biology
C. Quintarelli

09.20 New insights into AML Biology and their concrete and potential impact on treatment
I. Iacobucci

09.40 New insights in molecular Pathogenesis of AML: new targets?
S. Galimberti

10.00 Importance of Minimal Residual Disease Detection in Acute Myeloid Leukemia
C. Cerchione

10.20 Oral Communication 1 - Biology and MRD 1

10.40 Oral Communication 2 - Biology and MRD 2

11.00 Oral Communication 3 - Biology and MRD 3

11.20 Discussion

11.40 Coffee Break

SESSION 2

ACUTE LYMPHOBLASTIC LEUKEMIA WHAT IS CHANGING?

Chairs: F. Lanza, J. Ribera

12.00 How we manage Acute Lymphoblastic Leukemia in Europe
G. Martinelli



12.20 Ph-positive ALL – from old to novel treatments

C. Papayannidis

12.40 How monoclonal antibodies have changed the outcome of ALL patients

D. Cilloni

13.00 Oral Communication 4 - Acute Lymphoblastic Leukemia – What is changing? 1

13.20 Oral Communication 5 - Acute Lymphoblastic Leukemia – What is changing? 2

13.40 Discussion

14.00 Lunch

SESSION 3

ACUTE LYMPHOBLASTIC LEUKEMIA

TOWARD A NEW WORLD

Chairs: E. Jabbour, H. Kantarjian, M. Konopleva

15.00 Special Lecture

CART versus Monoclonal antibodies: eternal challenge in ALL

J. Ribera

15.20 How I manage Acute Lymphoblastic Leukemia at MD Anderson

H. Kantarjian

15.40 Immunotherapy in adult and elderly ALL

E. Jabbour

16.00 Early T-cell precursor Acute Lymphoblastic Leukemia and Ph-like ALL: from biology to treatment

J. Nitin

16.20 Special Lecture

Novel generations TKI in acute and chronic Ph-positive Leukemia

E. Jabbour



16.40 Special Lecture

CAR-T in Acute Leukemias: What's new?

J. Nitin

17.00 Oral Communication 6 - Acute Lymphoblastic Leukemia – Toward a new world 1

17.20 Oral Communication 7 - Acute Lymphoblastic Leukemia – Toward a new world 2

17.40 Oral Communication 8 - Acute Lymphoblastic Leukemia – Toward a new world 2

18.00 Discussion

18.20 Conclusions of 1st Day

C. Cerchione, G. Martinelli



29
06.22



08.30 Opening of 2nd Day
C. Cerchione, G. Martinelli

SESSION 4

NOVEL TARGETS AND TARGET THERAPIES IN ACUTE MYELOID LEUKEMIA

Chairs: C. Cerchione, N. Daver, G. Martinelli

09.00 Optimizing FLT3 inhibitor use
A. Isidori

09.20 Role of IDH inhibitors
G. Martinelli

09.40 Overcoming Environment-Mediated Drug Resistance in Acute Myeloid Leukemia
C. Cerchione

10.00 Management of NPM1 patients: from history to the future
M.P. Martelli

10.20 Oral Communication 9 – Novel targets and target therapies in Acute Myeloid Leukemia 1

10.40 Oral Communication 10 - Novel targets and target therapies in Acute Myeloid Leukemia 2

11.00 Discussion

11.20 Coffee Break

SESSION 5

PARTICULAR SETTINGS IN ACUTE MYELOID LEUKEMIA

Chairs: F. Ciceri, A. De La Fuente, A. Olivieri

11.40 Role of allogenic transplant in AML
A. Olivieri

12.00 Maintenance in AML
M. Gottardi



12.20 Secondary Acute Leukemias: what we have learnt and where are we going

G. Martinelli

12.40 Special Lecture

CAR-T versus allogeneic stem cell transplantation: from clinical trials to real world

F. Ciceri

13.00 Special Lecture

Target-therapy in elderly AML – present and future

N. Daver

13.20 Discussion

13.40 Lunch

SESSION 6

THE REVOLUTION IN ACUTE MYELOID LEUKEMIA

Chairs: H. Kantarjian, F. Locatelli, G. Martinelli

14.40 How I manage Acute Myeloid Leukemia at MD Anderson

H. Kantarjian

15.00 New targets and biological pathways in AML

G. Martinelli

15.20 How we integrate immunotherapy in AML management: Current and Future directions

N. Daver

15.40 Oral Communication 11 - Particular settings in Acute Myeloid Leukemia 1

16.00 Oral Communication 12 - Particular settings in Acute Myeloid Leukemia 2



16.20 Oral Communication 13 - The revolution in Acute Myeloid Leukemia

16.40 Oral Communication 14 - The revolution in Acute Myeloid Leukemia

17.00 Discussion

SESSION 7

PARTICULAR SUBSETS OF ACUTE LEUKEMIA

Chairs: F. Locatelli, G. Saglio

17.20 Special Lecture

The history of TKI: from Acute to Chronic Leukemias

G. Saglio

17.40 How I manage pediatric Acute Leukemias

F. Locatelli

18.00 How we manage BDPCN as new entity

G. Marconi

18.20 How we manage Acute Leukemias at MD Anderson Cancer Center
Madrid: From clinical trials to real life

A. De La Fuente

18.40 Oral Communication 15 - The revolution in Acute Myeloid Leukemia

19.00 Discussion

19.20 Conclusions and awards

C. Cerchione, G. Martinelli



Supported by an unrestricted educational grant from



Media Partner





Follow Us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is **#SOHOItaly22**

You can use it on **Facebook**, **Twitter**, **Instagram** and **Linkedin**.

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly

@SocietyofHemOnc

@IRSTufficiale

@MDAndersonNews

@pro_eventi

@GMartinelli2

@DottorClaudio

@DrHKantarjian

@Daver_Leukemia

**Enjoy & Share
your experience!**

Follow us





SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUT
ROMAGN
PER LO
DEI TUM
DINO
STUDIO
AMADORI